Hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride
• 化学式: C11H8ClN5O4
• 分子量: 309.66
• InChiKey: UMLFDVOHVJPDIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.73
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-(1H-imidazol-1-yl)-2,3(1H,4H)-quinoxalinedione hydrochloride 以53.7的产率得到Hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride
  参考文献：
  名称：

  J. Med. Chem. 1994, 37, 467-475

  摘要：

  DOI：

文献信息

• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Neuroprotective agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0778023A1

  公开（公告）日：1997-06-11

  This invention provides a method of using rapamycin, rapamycin 1,3-Diels Alder adduct with phenyltriazolinedione, rapamycin 42-ester with 4-[[4-(dimethylamino)phenyl]azo]benzenesulfonic acid, rapamycin 1,3-Diels Alder adduct with methyltriazolinedione, or rapamycin-O-benzyl-27-oxime as a neuroprotective agent.

  本发明提供了一种使用雷帕霉素、雷帕霉素 1,3-Diels Alder 加合物与苯基三唑啉二酮、雷帕霉素 42-酯与 4-[[4-（二甲基氨基）苯基]偶氮]苯磺酸、雷帕霉素 1,3-Diels Alder 加合物与甲基三唑啉二酮或雷帕霉素-O-苄基-27-肟作为神经保护剂的方法。
• AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
  申请人：Pfizer Products Inc.

  公开号：EP0900568A2

  公开（公告）日：1999-03-10

  The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.

  本发明涉及一种治疗哺乳动物多巴胺激动剂治疗相关运动障碍的方法，该方法包括向所述哺乳动物施用本文所定义的化合物，该化合物是 AMPA 受体的拮抗剂。本发明所述的多巴胺激动剂疗法通常用于治疗帕金森病等中枢神经系统疾病。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation
  申请人：Braincells, Inc.

  公开号：EP2275095A2

  公开（公告）日：2011-01-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。